Boehringer's zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 ( ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
The application for this investigational treatment is based on positive results from the Phase Ib Beamion LUNG-1, Cohort 1 trial that demonstrated an objective response rate of 71% in 75 previously treated patients with advanced NSCLC
HER2 ( ERBB2)-mutant advanced NSCLC is linked to poor prognosis and currently has limited treatment options1
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have HER2 ( ERBB2) mutations and who have received prior systemic therapy. The FDA grants Priority Review to applications for drugs that would offer significant improvements in the treatment, diagnosis, or prevention of serious conditions, with action expected within six months compared to 10 months under standard review. The Prescription Drug User Fee Act (PDUFA) action date is in the third quarter of 2025.
'We believe zongertinib has the potential to transform the care of previously treated patients with HER2 (ERBB2) -mutant advanced non-small cell lung cancer and are hopeful about the continued research in other tumor types and lines of therapy,' said Shashank Deshpande, Member of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. 'Priority Review illustrates the urgent need in this patient population and the possibility for zongertinib to be a groundbreaking innovation for patients with limited treatment options.'
The application was based on results from the positive Phase Ib Beamion LUNG-1 trial. Data from Cohort 1 (N=75) of the study, demonstrated an objective response rate (ORR) of 71% with six-month progression-free survival (PFS) and duration of response (DoR) rates of 69% and 73%, respectively, in patients with mutations in the HER2 tyrosine kinase domain.
Zongertinib had a safety profile with a low incidence of dose reductions (5%) and treatment discontinuations (3%). The majority of treatment-related adverse events (TRAEs) with zongertinib were mild in nature with diarrhea and rash being the most common all grade TRAEs, at 51% and 27% respectively. No new safety signals were observed. Grade 3 or higher TRAEs occurred in one patient treated with zongertinib. No treatment-related interstitial lung disease (ILD) cases were reported.
'Personalized medicine has revolutionized cancer treatment,' said GO2 for Lung Cancer's Chief Scientific Officer, Courtney Granville. 'Early screening and biomarker testing for mutations provide critical information to guide targeted therapies in personalized medicine. This filing acceptance represents a significant step toward offering another option for individuals with a HER2 ( ERBB2) diagnosis, bringing hope and direction to cancer patients.'
Zongertinib was previously granted Breakthrough Therapy Designation and Fast Track Designation by the FDA. The FDA's Breakthrough Therapy designation is intended to expedite the development and review of a medicine that is intended to treat a serious or life-threatening disease, and preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available treatments. The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. In addition to the FDA designations, Japan's Pharmaceuticals and Medical Devices Agency recently granted Orphan Drug Designation to zongertinib.
About the Beamion clinical trial program
Beamion LUNG-1 ( NCT04886804) is an open-label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib as monotherapy in people with unresectable or metastatic solid tumors with HER2 ( ERBB2) alterations. Beamion LUNG-2 is a Phase III, open label, randomized, active-controlled study that is enrolling patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 ( ERBB2) tyrosine kinase domain mutations to evaluate zongertinib compared with standard of care.
About zongertinib
Zongertinib (also known as BI 1810631) is an investigational, irreversible tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 ( ERBB2) while sparing EGFR, thereby limiting associated toxicities. This orally administered, targeted treatment is being developed for HER2 ( ERRB2) - mutant advanced non-small cell lung cancer (NSCLC) and additional clinical studies with zongertinib are ongoing in solid tumors with HER2 alterations.
About non-small cell lung cancer (NSCLC)
Lung cancer claims more lives than any other cancer type and the incidence is set to increase to over 3 million cases worldwide by 2040.2 NSCLC is the most common type of lung cancer.3 Due to a lack of symptoms and misdiagnoses,4 most patients diagnosed with NSCLC present at stage III or IV, where the disease has metastasized locally or to other organs.5 Fewer than 3 in 10 patients are alive five years after a diagnosis of HER2 ( ERBB2)-mutant advanced NSCLC.6 People living with advanced NSCLC can experience a detrimental physical, psychological, and emotional impact on their daily lives. There remains a high unmet need for additional treatment options for people living with advanced NSCLC. HER2 ( ERBB2) mutations occur in approximately 2–4% of NSCLC cases and are associated with a poor prognosis and higher incidence of brain metastases.7,8 Mutations in HER2 ( ERBB2) can lead to overexpression and overactivation, which can in turn result in uncontrolled cell production, inhibition of cell death and promotion of tumor growth and spread.9
About Boehringer Ingelheim in oncology
We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Boehringer Ingelheim's generational commitment to driving scientific innovation is reflected by the company's robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. Boehringer's ambition in oncology is to take a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringer-ingelheim.com/us.
1Nützinger J, Lee JB, Low JL, et al. Lung Cancer. 2023;186:107385. doi:10.1016/j.lungcan.2023.107385
2International Agency for Research on Cancer – World Health Organization. Rates of trachea, bronchus and lung cancer. Available at: https://gco.iarc.fr/tomorrow/en (Accessed: January 2025).
3Zappa C & Mousa Non-small cell lung cancer: current treatment and future advances, Transl Lung Cancer Res. 2016 Jun; 5(3): 288–300.
4American Cancer Society. Signs and Symptoms of Lung Cancer Available at: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/signs-symptoms.html (Accessed: January 2025).
5Casal-Mouriño, A. et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506-518.
6National Cancer Institute Surveillance, Epidemiology, and End Results (SEER). https://seer.cancer.gov/statfacts/html/lungb.html (Accessed: January 2025).
7Baraibar I, et al. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Crit Rev Oncol Hematol. 2020;148:102906.
8Li, B.T. et al. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer. N Engl J Med. 2022;386:241–51.
9Galogre M, et al. A review of HER2 overexpression and somatic mutations in cancers, Critical Reviews in Oncology/Hematology, Volume 186, 2023, 103997
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Combination Cancer Therapies Surge: The Young Adult Treatment Revolution
As cancer rates climb 30% among adults under 50, combination immunotherapy companies are advancing breakthrough treatments and institutional investors are committing $243.62 billion to capture the rapidly expanding precision oncology market. A medical crisis is reshaping the cancer treatment landscape. Young adults under 50 are experiencing unprecedented cancer rates, with aggressive tumors requiring innovative combination approaches that go far beyond traditional single-drug therapies. According to Memorial Sloan Kettering Cancer Center, cancer incidence rates in women under 50 are now 82% higher than their male counterparts, up from 51% in 2002. The American Cancer Society reports that colorectal cancer has become the leading cause of cancer deaths among young men and the second leading cause among young women, fundamentally changing treatment priorities across the oncology spectrum. The market response reflects this urgency. Mordor Intelligence projects the global cancer therapy market will surge from $243.62 billion in 2025 to $403.99 billion by 2030, reflecting a 10.64% CAGR driven by demand for combination therapies specifically designed to combat the more aggressive cancers plaguing younger demographics. Keep reading to discover how combination immunotherapy approaches are revolutionizing treatment for young adult cancer patients and which companies are positioned to dominate this rapidly evolving market. For a detailed analysis of one company leading this transformation, click here. Leading Companies in the Combination Therapy Revolution Combination immunotherapy is attracting significant institutional investment, with these companies making strategic moves: AstraZeneca PLC (NASDAQ: AZN) --- AstraZeneca recently received FDA Priority Review and Breakthrough Therapy Designation for its Imfinzi immunotherapy in early-stage gastric cancers, with FDA decision anticipated in Q4 2025. The perioperative combination regimen showed a 29% reduction in disease progression risk, positioning the company to capture significant market share as gastric cancers increasingly affect younger populations with more aggressive disease patterns. Bristol Myers Squibb Company (NYSE: BMY) --- Bristol Myers Squibb recently secured FDA approval for its Opdivo-Yervoy combination as first-line treatment for unresectable liver cancer, converting a previous accelerated approval. The dual checkpoint inhibitor regimen directly competes with rival immunotherapy combinations and offers potential for longer survival compared to traditional targeted therapies, particularly relevant as liver cancers show rising incidence in younger adults. Amgen Inc. (NASDAQ: AMGN) --- Amgen recently gained FDA approval for Imdelltra, its breakthrough bispecific T-cell engager for extensive-stage small-cell lung cancer, with pricing at $31,500 per first cycle. The drug demonstrated a tripling of survival duration to 14.3 months median overall survival in a disease where median survival typically reaches only 5 months, addressing the urgent need for effective treatments in the deadliest form of lung cancer. Pfizer Inc. (NYSE: PFE) --- Pfizer recently showcased breakthrough data across its oncology portfolio at ASCO 2025, featuring combination approaches in breast, genitourinary, and thoracic cancers. The company's Braftovi combination doubled survival time for patients with aggressive colorectal cancer in late-stage trials, representing significant progress for a cancer type that disproportionately affects younger adults with traditionally poor prognosis and limited treatment options. The $403.99 Billion Combination Therapy Opportunity The convergence of rising young adult cancer rates and breakthrough combination immunotherapies is creating unprecedented market expansion across every segment of oncology treatment. Read: Mining Stocks Finally Wake Up as Gold Stays Hot Above $3,300 $40 Silver Breakout Imminent as Miners Enter High-Momentum Phase Encryption Is Dying—Here's What Comes Next for Cyber Defense FDA Fast-Track Cancer Treatments Drive $900B Market Growth Forecast Mining Stocks Outpace Gold's Historic Rally as Sector Primes for Breakout According to Mordor Intelligence, the global cancer therapy market will reach $403.99 billion by 2030, with combination immunotherapies representing the fastest-growing segment. The shift toward treating younger patients with more aggressive cancers requiring multi-drug approaches is fundamentally altering treatment economics and creating new revenue opportunities for companies developing sophisticated combination regimens. Precedence Research forecasts the cancer therapeutics market will expand from $194.67 billion in 2024 to $469.38 billion by 2034, representing a 9.20% CAGR. This explosive growth is being driven by the unique challenges of treating younger patients whose cancers often resist single-agent therapies and require novel combinations of checkpoint inhibitors, targeted therapies, and next-generation immunomodulators specifically designed for aggressive tumor biology. Global Market Insights projects the oncology market will reach $866.1 billion by 2034, growing at a 10.8% CAGR. The market expansion is being accelerated by the urgent need to address the 30% surge in young adult cancer cases projected through 2030, with combination therapies representing the most promising approach to combat the treatment-resistant, aggressive cancers increasingly diagnosed in this demographic. The Bottom Line The combination therapy revolution is accelerating rapidly, driven by the unprecedented cancer epidemic affecting young adults who require more sophisticated treatment approaches than traditional single-drug regimens can provide. With aggressive cancers becoming more prevalent in younger demographics, the demand for innovative combination immunotherapies is creating massive market opportunities. Institutional investors are positioning for explosive growth as companies develop next-generation combination platforms specifically designed to address the unique molecular characteristics and treatment resistance patterns exhibited by cancers in younger patients. While the companies mentioned represent established leaders in combination therapy development, one innovative biotech has quietly advanced a viral immunotherapy platform that combines multiple mechanisms of action in a single treatment approach. To learn more about this emerging opportunity, click here.
Medscape
an hour ago
- Medscape
Where Do We Stand on COVID Vaccine Recommendations in 2025?
This transcript has been edited for clarity. This edition of Medicine Matters takes a closer look at the future of COVID vaccines for fall 2025. The current status of COVID vaccines can be best described as unclear. There is confusion, conflicts of interest, and chaos. A lot has happened, so here is a brief recap of major developments over the past few months. New COVID Vaccine Approvals and a New Vaccine Formula On May 22, the FDA announced the new COVID vaccine formula, a monovalent JN.1 lineage — preferably using the LP.8.1 strain. On May 16, the FDA fully licensed the Novavax COVID vaccine but limited its use to those 65 or older, and to those aged 12-64 years with at least one high-risk medical condition. Later in May, these same restrictions were applied to the approval of Moderna's new lower-dose mRNA COVID vaccine, mNEXSPIKE. FDA's 'New' Way of Evaluating COVID Vaccines On May 20, in a sounding board article in The New England Journal of Medicine , the FDA Commissioner, Martin Makary, MD, MPH, and the Center for Biologics Evaluation and Research Director, Vinay Prasad, MD, MPH, announced new changes on how FDA would evaluate COVID vaccines. Additional clinical trials, including placebo-controlled trials using a saline placebo, would be required. They said the FDA anticipates that it will make favorable risk-benefit findings for adults 65 or older and for those 6 months or older with one or more risk factors that put them at high risk for severe COVID outcomes. Both pregnancy and recent pregnancy were on their list of underlying medical conditions that increase a person's risk for severe COVID. HHS Secretary Kennedy Issues His Own COVID Vaccine Directive One week later, on May 27, HHS Secretary Kennedy issued his own directive and unilaterally removed COVID vaccines from the immunization schedule for healthy children and for pregnant women. He made this announcement on social media. No new evidence was cited to support this decision. Absent from this announcement was any representative from the CDC or ACIP. Kennedy's actions triggered the resignation of several key and well-respected CDC employees in the COVID vaccine space. I've served on ACIP's COVID vaccine work group since the beginning. Our work group had not been consulted. In fact, work group meetings had been suspended. ACIP Members Ousted Before June Meeting Updated COVID vaccine recommendations had been expected to be on the June ACIP meeting agenda. But on June 9, just 2 weeks prior to the June ACIP meeting, HHS Secretary Kennedy removed all 17 ACIP members and then replaced them with his own handpicked group of eight — many of whom have preconceived bias against vaccines. At the June meeting, there was not a vote on COVID vaccines. However, CDC staff did present updates on COVID epidemiology. Here are some highlights: Most pediatric hospitalizations (57%) occur in children less than 2 years of age. Most hospitalized children in this age group have no underlying medical conditions. Rates of COVID-associated hospitalizations are highest among infants less than 6 months of age, followed by those aged 6-23 months. None of the COVID vaccine products are approved for infants under 6 months of age, so protection can only come from maternal antibodies. The majority (89%) of children and adolescents hospitalized for COVID had not received a dose of the most recently recommended vaccine. These data show why Kennedy's directive to withhold COVID vaccines from children and pregnant women is so absolutely ridiculous. FDA Mandates, Restrictions, and Authorizations Also on June 25, the FDA mandated a label change for COVID vaccines, warning about risk for myocarditis — but did not mention that the risk for myocarditis from COVID infection is greater than the risk for myocarditis after COVID vaccination. In July, more restrictions were placed on COVID vaccines for young children. Moderna's mRNA COVID vaccine, Spikevax, was FDA-approved for everyone aged 65 years or older. Spikevax was also approved for individuals aged 6 months to 64 years old, but only those with at least one medical condition that puts them at increased risk for COVID. Then in August, news reports indicated that Pfizer's COVID vaccine may lose its emergency use authorization for healthy children under the age of 5 years. Although it was expected to be available for children aged 5-11 years, no official announcement has been made. To be clear, if the FDA doesn't renew Pfizer's authorization (or fully approve the vaccine) for children 6 months through 4 years old, healthy children in that age group will have no officially sanctioned option for COVID vaccination. The only way to administer COVID vaccination to healthy children would be to give the Moderna vaccines off-label. If that happens, we could end up having a vaccine shortage. And COVID hasn't gone away. On August 5, CDC's wastewater analysis showed that COVID-19 infections were growing or likely growing in 45 states — indicating a late summer COVID wave. Medical Organizations Step Up to the Plate On August 19, the Vaccine Integrity Project released "From Data to Decisions: The Evidence Base for 2025 Fall/Winter Immunizations." This livestream presentation looked at recently published and publicly available data and found no notable safety or effectiveness issues. Also on August 19, the American Academy of Pediatrics (AAP) issued its own evidence-based immunization schedule for children. For COVID protection, AAP recommends the COVID vaccine for infants and children 6 months through 23 months of age — recognizing that children in this age group are at highest risk for severe COVID. AAP also recommends a single dose of age-appropriate COVID vaccine for all children and adolescents age 2 through 18 years in the following risk groups: Children at high risk for severe COVID Residents of long-term care facilities or other congregate settings Children who've never been vaccinated against COVID Children with household contacts at high risk for severe COVID AAP also recommends that the COVID vaccine be available for children aged 2-18 years who do not fall into these risk groups, but whose parent or guardian desires them to have the protection of the vaccine. AAP recommends that the most updated version of the COVID-19 vaccine available should be used. We can likely expect more medical organizations to issue recommendations based on this new Vaccine Integrity Project review. Concern About the Integrity of Future COVID Vaccination Recommendations According to the ACIP website, another ACIP meeting is planned for August/September, but no date is currently given. We can only hope there will be a truly evidence-based vote on the new-formula COVID vaccines — but I'm not optimistic. On July 31, HHS Secretary Kennedy removed ACIP liaisons from the vaccine work groups. These work groups review vaccine data and develop recommendations that are then presented to ACIP at the public meetings for vote. Now, the work groups are populated only with Kennedy's new ACIP members — most of whom have a proven history of bias against vaccines — and CDC staff that could ostensibly be fired by Kennedy if they don't do what he says. Without liaisons and work groups, we have no way of ensuring that evidence-based science is being applied as these work group recommendations are developed and presented to the full ACIP. To make matters worse, Kennedy recently cut nearly $500 million in research funding aimed at developing better mRNA vaccines; 22 research grants for COVID and flu vaccines were targeted. The reason he gave for these cuts was that vaccines made using this platform were not effective and were unsafe. That's not true. The head of the NIH, Jay Bhattacharya, MD, PhD, offered another explanation for the cancellation. He said the platform wasn't viable because the public doesn't trust it. These cancellations leave us highly vulnerable for the next pandemic — and there will eventually be one. It also puts development of lifesaving mRNA-based cancer treatments at risk. Misinformation Can Be Dangerous On Friday, August 8, a shooter unleashed nearly 500 rounds at CDC buildings in Atlanta. One security officer was killed. The shooter died of a self-inflicted gunshot wound. Authorities found documents in his house expressing discontent with COVID vaccines. Susan Monarez, the new CDC director, was quoted in news reports as saying, "We know that misinformation can be dangerous..." As we also know, Kennedy has been most prominent in spreading misinformation and voicing distrust of vaccines, long before he even became HHS secretary. The case against mRNA technology offered by Kennedy and his new team is unbound by science or evidence. The attack on mRNA vaccines is unscientific foolishness perpetuated by people with a bias against vaccines. They use scientific words in a most unscientific way to create misinformation, vaccine hesitancy, confusion, and mistrust. The recent shooting at CDC is an example of mistrust fueled by vaccine skeptics. Let's not forget it was mRNA vaccines, developed in 1 year through Operation Warp Speed, that saved the world during the COVID pandemic. Billions of doses of mRNA COVID vaccines have been administered worldwide, making them among the most studied vaccines in history. mRNA vaccines are safe and effective. No other vaccine platform can produce vaccines so quickly. HHS Secretary Kennedy's assault on the viability of ACIP and the destruction of our vaccine development infrastructure continue. We still don't have any ACIP recommendations for updated COVID vaccines for fall. We still don't have a date set for the August/September ACIP meeting, and when that meeting date is set, will a vote on COVID vaccines be on that agenda? And if it is, will it be truly evidence-based? The CDC and the HHS secretary are supposed to put forward vaccine policy that can bring health and happiness and prevent death and illness in our country. America's physicians must stand up for our patients, as should everyone who believes in public health. We must push back on misinformation, medical foolishness, and quackery. And the chain of events I have described in this segment is exactly that. Misinformation leads to mistrust in vaccines, mistrust reduces vaccine uptake, and reduced vaccine uptake sickens and kills our patients.
Yahoo
2 hours ago
- Yahoo
Was the potentially radioactive shrimp sold in your state? See map.
A recall has been issued for frozen shrimp sold at Walmart in 13 states that may have been contaminated with a radioactive chemical, the Food and Drug Administration said. On Tuesday, Aug. 19, the FDA advised the recall after it detected Cesium-137 (Cs-137), a radioactive chemical "produced by nuclear fission for use in medical devices and gauges," according to the Environmental Protection Agency. The chemical was detected in four U.S. ports across the country and in a sample of breaded shrimp, the FDA stated. "Although testing to date has not confirmed the presence of contamination in any product in commerce, the product appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern," the FDA advised. The FDA is investigating the situation. 82681335007 Which states sold the recalled frozen shrimp? The recalled shrimp were sold in the following 13 states: Alabama Arkansas Florida Georgia Kentucky Louisiana Mississippi Missouri Ohio Oklahoma Pennsylvania Texas West Virginia More recalls: Over 78,000 Jeep Wrangler vehicles recalled. Here's why. Ports that received contaminated shipping containers The four ports where the FDA detected contaminated shipping containers are in the following cities: Los Angeles Houston Miami Savannah, Georgia Which products were recalled? The recall is targeted at 2-pound bags of Great Value brand Frozen Raw Ez Peel Tail-On Farm-Raised White Vannamei Shrimp. Lot codes and best by dates include the following: Lot code: 8005540-1; best by date: 3/15/2027 Lot code: 8005538-1; best by date: 3/15/2027 Lot code: 8005539-1; best by date: 3/15/2027 The shrimp products are processed by PT. Bahari Makmur Sejati, a company in Indonesia doing business as BMS Foods, according to the FDA. What to do if you have recalled shrimp If you have a package of the recalled Walmart shrimp at home, throw it away and do not eat or serve it, the FDA notice says. Distributors and retailers should dispose of the product and refrain from selling it. Anybody who fears they may have been exposed to elevated levels of cesium should contact their medical providers. To submit a complaint or report an adverse reaction, consumers can visit the FDA's Industry and Consumer Assistance portal. PT. Bahari Makmur Sejati placed under an import alert PT. Bahari Makmur Sejati has also been placed on an import alert for chemical contamination, which prevents any of the company's food products from entering the United States until it resolves any conditions that could have caused the exposure. The FDA is working with Indonesian seafood regulatory authorities to investigate the cause of the contamination. What is Cesium-137 (Cs-137) and why is it regulated? Cs-137 is a radioisotope of cesium, meaning it is a chemical element that emits radiation as it breaks down. It is man-made and is produced by nuclear fission, according to the FDA. In the United States, it is used in medical devices and measurement gauges, such as industrial devices that measure the thickness of materials. "It is also one of the byproducts of nuclear fission processes in nuclear reactors and nuclear weapons testing," the EPA stated. Because it is widespread around the globe, trace amounts can be found in the environment, including in soil, food and air, the FDA. Agencies, including the FDA and U.S. Customs & Border Protection, test for, monitor and regulate the presence of the substance due to the risks associated with long-term exposure. Low-level radiation exposure over time can lead to serious health complications, the FDA said. Exposure to Cs-137 alone can cause burns, acute radiation sickness, cancer and death. As a result, the governing agencies restrict potential exposure to lessen the possibility of these long-term impacts. Julia is a trending reporter for USA TODAY. Connect with her on LinkedIn, X, Instagram and TikTok: @juliamariegz, or email her at jgomez@ This article originally appeared on USA TODAY: Which states received the potentially radioactive shrimp? See map.
